COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D08ADX
|
|||
Drug Name |
Clevudine
|
|||
Synonyms |
Clevudine; 163252-36-6; L-FMAU; Levovir; UNII-IN51MVP5F1; Clevudine (Levovir); IN51MVP5F1; Clevudine [USAN:INN]; C10H13FN2O5; Revovir; AK106264; Clevudine (USAN); Clevudine (Form 2); PubChem23138; MLS006011168; SCHEMBL233494; CHEMBL4588; Clevudine
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Coronavirus Disease 2019 (COVID-19) | Phase 2 | [1] | |
Other Indication | Hepatitis B | Phase 4 | [2] | |
Therapeutic Class |
Antiviral Agents
|
|||
Structure |
Download2D MOL |
|||
Formula |
C10H13FN2O5
|
|||
Canonical SMILES |
CC1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)F
|
|||
InChI |
1S/C10H13FN2O5/c1-4-2-13(10(17)12-8(4)16)9-6(11)7(15)5(3-14)18-9/h2,5-7,9,14-15H,3H2,1H3,(H,12,16,17)/t5-,6+,7-,9-/m0/s1
|
|||
InChIKey |
GBBJCSTXCAQSSJ-XQXXSGGOSA-N
|
|||
CAS Number |
CAS 163252-36-6
|
|||
PubChem Compound ID | ||||
ChEBI ID |
CHEBI:135964
|
References | Top | |||
---|---|---|---|---|
1 | ClinicalTrials.gov (NCT04347915) The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19. U.S. National Institutes of Health. | |||
2 | ClinicalTrials.gov (NCT00501124) Safety and Efficacy Study of Clevudine Compared With Clevudine and Vaccine in Patient With HBeAg(+) Chronic HBV. U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.